Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

NCT06307249 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Solid Tumor
Colorectal Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Targeted Therapy
Chemotherapy
Immunotherapy
Precision Therapy

Interventions

GENETIC: SNP
DRUG: Palbociclib 125mg
DRUG: Bevacizumab

Sponsor

Lebanese University

Collaborators

[object Object]